US Bancorp DE lowered its position in shares of Balchem Co. (NASDAQ:BCPC - Free Report) by 19.9% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 6,477 shares of the basic materials company's stock after selling 1,606 shares during the quarter. US Bancorp DE's holdings in Balchem were worth $1,056,000 at the end of the most recent reporting period.
Several other institutional investors have also recently modified their holdings of the company. Westside Investment Management Inc. acquired a new stake in shares of Balchem in the third quarter worth $27,000. R Squared Ltd purchased a new stake in shares of Balchem in the fourth quarter worth about $29,000. Wilmington Savings Fund Society FSB acquired a new stake in Balchem during the third quarter worth about $35,000. Venturi Wealth Management LLC acquired a new stake in Balchem during the fourth quarter worth about $95,000. Finally, Pacer Advisors Inc. raised its position in Balchem by 18.4% during the fourth quarter. Pacer Advisors Inc. now owns 1,113 shares of the basic materials company's stock valued at $181,000 after acquiring an additional 173 shares in the last quarter. 87.91% of the stock is currently owned by hedge funds and other institutional investors.
Balchem Price Performance
BCPC traded down $1.10 during trading on Thursday, hitting $166.38. The company's stock had a trading volume of 64,406 shares, compared to its average volume of 138,639. The company has a current ratio of 1.99, a quick ratio of 1.16 and a debt-to-equity ratio of 0.19. The business's fifty day simple moving average is $163.51 and its 200 day simple moving average is $169.82. The firm has a market capitalization of $5.41 billion, a price-to-earnings ratio of 42.34, a P/E/G ratio of 4.41 and a beta of 0.63. Balchem Co. has a twelve month low of $137.69 and a twelve month high of $186.03.
Balchem (NASDAQ:BCPC - Get Free Report) last released its earnings results on Friday, February 21st. The basic materials company reported $1.03 EPS for the quarter, missing analysts' consensus estimates of $1.11 by ($0.08). Balchem had a return on equity of 11.37% and a net margin of 13.47%. The company had revenue of $240.00 million for the quarter, compared to analysts' expectations of $239.96 million. On average, equities research analysts forecast that Balchem Co. will post 4.64 EPS for the current fiscal year.
Wall Street Analyst Weigh In
A number of brokerages have recently commented on BCPC. Sidoti raised shares of Balchem to a "hold" rating in a research note on Tuesday, February 25th. StockNews.com lowered shares of Balchem from a "buy" rating to a "hold" rating in a research report on Tuesday, February 25th. Finally, HC Wainwright reiterated a "buy" rating and issued a $190.00 price objective on shares of Balchem in a research report on Monday, February 24th.
Read Our Latest Stock Report on Balchem
Balchem Company Profile
(
Free Report)
Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.
Featured Articles
Before you consider Balchem, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Balchem wasn't on the list.
While Balchem currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
